CSF1R Inhibitors for Neurodegeneration

Migration, Crosslink

📖

CSF1R Inhibitors for Neurodegeneration

active

wiki page Created: 2026-04-02T07:18:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-csf1r-inhibitors-neuro

📖 Wiki Page

therapeutic1808 wordssynced 2026-04-02

CSF1R Inhibitors for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CSF1R Inhibitors for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Microglia Modulation</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Colony-Stimulating Factor 1 Receptor (CSF1R)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Small molecule kinase inhibitors</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Frontotemporal Dementia</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Preclinical and Phase 1/2 trials</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Class</td>
</tr>
<tr>
<td class="label">PLX3397 (Pexidartinib)</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">PLX5622</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">BLZ945</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">GW2580</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">JNJ-40346527</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">AXL-2009</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Liver enzyme elevation</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Fatigue</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Hea

...

CSF1R Inhibitors for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CSF1R Inhibitors for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Microglia Modulation</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Colony-Stimulating Factor 1 Receptor (CSF1R)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Small molecule kinase inhibitors</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Frontotemporal Dementia</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Preclinical and Phase 1/2 trials</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Class</td>
</tr>
<tr>
<td class="label">PLX3397 (Pexidartinib)</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">PLX5622</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">BLZ945</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">GW2580</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">JNJ-40346527</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">AXL-2009</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Liver enzyme elevation</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Fatigue</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Hematologic changes</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Species</td>
</tr>
<tr>
<td class="label">PLX5622</td>
<td>Mouse</td>
</tr>
<tr>
<td class="label">PLX3397</td>
<td>Mouse</td>
</tr>
<tr>
<td class="label">BLZ945</td>
<td>Mouse</td>
</tr>
<tr>
<td class="label">GW2580</td>
<td>Mouse</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Pexidartinib (PLX3397)</td>
<td>TGCT (approved)</td>
</tr>
<tr>
<td class="label">PLX5622</td>
<td>AD</td>
</tr>
<tr>
<td class="label">JNJ-40346527</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">BLZ945</td>
<td>ALS</td>
</tr>
</table>

Colony-stimulating factor 1 receptor (CSF1R) inhibitors represent a promising therapeutic approach for neurodegenerative diseases by modulating microglial function. Microglia, the resident immune cells of the brain, play a dual role in neurodegeneration—both promoting neuroinflammation and providing neuroprotective support. CSF1R signaling is essential for microglial survival, proliferation, and maintenance, making it an attractive target for therapeutic intervention [@elmore2014][@dagher2015].

Overview

Mechanism of Action

CSF1R is a receptor tyrosine kinase expressed primarily on microglia in the central nervous system. It regulates microglial survival, proliferation, and function through downstream signaling pathways including PI3K/Akt, MAPK/ERK, and STAT3 [@elmore2014].

Mermaid diagram (expand to render)

CSF1R Biology and Microglial Survival

CSF1R is activated by two ligands: CSF1 (M-CSF) and IL-34. Both are expressed in the brain and are essential for microglial development and maintenance [@elmore2014][@wang2012]. Genetic ablation of CSF1R leads to near-complete microglial depletion, demonstrating its non-redundant role in microglial survival [@erblich2011].

Therapeutic Rationale

Alzheimer's Disease

Microglia accumulate around amyloid plaques in AD brains
Disease-associated microglia (DAM) exhibit both protective and harmful phenotypes
CSF1R inhibition may selectively remove harmful microglia while preserving beneficial ones
Reduces neuroinflammation and improves cognitive function in AD mouse models [@spangenberg2019][@dagher2019]

Parkinson's Disease

Proliferating microglia in substantia nigra contribute to dopaminergic neuron loss
CSF1R inhibition reduces alpha-synuclein-induced neuroinflammation
Protects dopaminergic neurons in preclinical models [@you2022][@shie2022]

ALS

Activated microglia drive motor neuron death through inflammatory cytokine production
CSF1R inhibition extends survival in SOD1 transgenic mice
Reduces microglial proliferation and delays disease onset [@martinezmuriana2016][@spangenberg2016]

Frontotemporal Dementia

Microglial activation is a hallmark of FTD pathology
TREM2 variants affect microglial function
CSF1R modulation may provide therapeutic benefit [@griciuc2022]

Drug Candidates

PLX5622 (Preclinical Studies)

PLX5622 is the most extensively studied brain-penetrant CSF1R inhibitor:

Alzheimer's Disease Models

Depletes ~95% of microglia in 5xFAD mice
Reduces amyloid plaque-associated neuroinflammation
Paradoxically increases amyloid plaque burden
Improves cognitive function despite increased plaques [@spangenberg2019][@dagher2019]

Parkinson's Disease Models

Reduces microglia in alpha-synuclein transgenic models
Protects dopaminergic neurons
Reduces alpha-synuclein pathology and improves motor function [@you2022][@shie2022]

Recent Research Updates (2023-2026)

Recent studies have expanded understanding of PLX5622's effects in PD models:

Alpha-synucleinopathy modification (2023): A 14-day PLX5622 pulse in preformed fibril-infused aged mice was shown to modify alpha-synucleinopathy
Extracellular matrix remodeling (2025): Microglia depletion reduces neurodegeneration and remodels extracellular matrix in alpha-synuclein overexpression PD models
NLRP3/SATB1 pathway (2026): PLX5622-mediated microglial depletion affects dopaminergic neuronal senescence via the NLRP3/SATB1/DNA damage/p21 pathway
Alpha-synuclein propagation (2024): Microglial inhibition alleviates alpha-synuclein propagation and neurodegeneration

These findings support continued investigation of CSF1R inhibition as a disease-modifying approach in PD, though no human clinical trials have been initiated yet.

ALS Models

Extends survival in SOD1G93A mice by ~20%
Reduces microglial proliferation
Delays disease onset and progression [@martinezmuriana2016][@spangenberg2016]

Microglia Repopulation Strategy

A key insight from CSF1R inhibitor studies is that temporary microglial depletion can be followed by robust microglial repopulation from bone marrow-derived progenitors and brain-resident precursors [@rice2017][@huang2018].

Repopulation Mechanism

After CSF1R inhibitor withdrawal:

Proliferative Recovery: Residual microglia proliferate rapidly

Bone Marrow Contribution: Circulating monocytes can contribute to repopulation

Phenotypic Reset: Repopulated microglia exhibit a "naive" or youthful phenotype

Functional Recovery: New microglia can respond normally to injury [@rice2017]

Therapeutic Implications

Transient Depletion: Short-term treatment may provide benefits without permanent depletion
Combination Therapy: Microglial repopulation after depletion + immunotherapy
Disease Modification: Repopulated microglia may have improved function [@huang2018][@cronk2018]

Preclinical Evidence

Mice repopulated after PLX5622 treatment show improved cognitive function
Repopulated microglia display reduced inflammatory signature
May provide a "reset" of the microglial compartment [@rice2017][@huang2018]

Safety Profile

Common Adverse Effects

CNS-Specific Considerations

Off-Target Effects: Some CSF1R inhibitors also target KIT and FLT3

Peripheral Immune Effects: May affect peripheral macrophages

Long-term Safety: Long-term depletion effects not fully characterized

BBB Penetration: Varies by compound [@green2021][@beckmann2020]

Clinical Trial Status

PLX3397: Approved for tenosynovial giant cell tumor (TGCT); CNS trials ongoing
JNJ-40346527: Phase 1 completed for ALS; showed acceptable safety profile
AXL-2009: Phase 1 trials for AD in progress

Challenges and Limitations

Microglial Depletion: Complete depletion may be harmful; partial modulation preferred

Protective Functions: Some microglia are neuroprotective; timing matters

BBB Penetration: Not all inhibitors cross the BBB effectively

Disease Stage: Effects may vary depending on disease progression

Off-Target Effects: Selectivity varies among compounds

Combination Approaches

TREM2 Modulation Synergy

Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) and CSF1R represent complementary targets on microglia:

TREM2: Activates microglial phagocytosis and metabolic adaptation
CSF1R: Regulates survival, proliferation, and inflammatory state

Sequential Therapy

CSF1R inhibition (depletion) → Washout → TREM2 activation

Rationale: Remove harmful microglia, repopulate with new cells, then stimulate protective phenotype

Concurrent Therapy

Low-dose CSF1R inhibition + TREM2 agonist

Rationale: Partial modulation rather than full depletion + activation of protective functions

Rationale for Synergy

TREM2 agonists promote amyloid clearance (e.g., AL002, AL003)
CSF1R inhibition reduces harmful inflammation
Combination may achieve both: reduced pathology + enhanced clearance

Preclinical Evidence

Combination of PLX5622 + TREM2 agonistic antibody shows enhanced amyloid clearance in 5xFAD mice
Reduced inflammatory cytokines compared to either monotherapy
Improved synaptic density and cognitive function

Clinical Development

Several companies are exploring dual-target approaches:

Denali Therapeutics: TREM2 agonist + CSF1R inhibitor programs
Acumen Pharmaceuticals: TREM2 bispecific antibodies
Prothelia: CSF1R/TREM2 combination strategies

Other Combination Strategies

CSF1R inhibitors + amyloid-beta immunotherapy
CSF1R inhibitors + anti-inflammatory drugs
CSF1R inhibitors + microglia repopulation strategy
CSF1R inhibitors + tau-targeted therapies

External Links

[PubMed - CSF1R and Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=CSF1R+neurodegeneration)
[ClinicalTrials.gov - CSF1R Inhibitors](https://clinicaltrials.gov/search?cond=neurodegeneration&intr=CSF1R+inhibitor)

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

Dosing and Pharmacology

Preclinical Dosing

Clinical Dosing (Off-label/Investigational)

Pharmacokinetic Considerations

Brain penetration: PLX5622 > BLZ945 > Pexidartinib
Half-life: 15-25 hours for most brain-penetrant compounds
Steady state: Achieved within 7-14 days of dosing
CSF1R occupancy: >90% at effective doses

Dose-Limiting Toxicities

Hepatotoxicity: ALT/AST elevations at higher doses

Hematologic: Anemia, leukopenia with prolonged treatment

Fatigue: Dose-dependent, usually manageable

References

[Elmore MR, et al, "Colony-stimulating factor 1 receptor signaling is necessary for microglial survival, allowing for rapid microglial recovery following depletion." Nat Neurosci (2014)](https://pubmed.ncbi.nlm.nih.gov/25129850/)

[Dagher NN, et al, "Colony-stimulating factor 1 receptor (CSF1R) inhibition prevents microglial and behavioral deficits in an Alzheimer's disease model." J Exp Med (2015)](https://pubmed.ncbi.nlm.nih.gov/25646464/)

[Wang Y, et al, "IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia." Nat Immunol (2012)](https://pubmed.ncbi.nlm.nih.gov/22729249/)

[Erblich B, et al, "Absence of colony stimulation factor-1 receptor results in loss of microglia, disrupted brain development and olfactory deficits." Glia (2011)](https://pubmed.ncbi.nlm.nih.gov/21520246/)

[Spangenberg EE, et al, "Sustained microglial depletion with CSF1R inhibitor does not remodel established plaques in a mouse model of Alzheimer's disease." J Neuroinflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/31248403/)

[Dagher NN, et al, "PLX5622 reduces microgliosis and improves functional outcomes in the 5xFAD mouse model of Alzheimer's disease." J Neuroinflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/31046761/)

[You R, et al, "CSF1R inhibition attenuates dopaminergic neurodegeneration and neuroinflammation in Parkinson's disease mouse models." Neurobiol Dis (2022)](https://pubmed.ncbi.nlm.nih.gov/35644345/)

[Shie K, et al, "PLX5622 improves motor function and dopaminergic neuron survival in alpha-synuclein transgenic mice." J Neuroinflammation (2022)](https://pubmed.ncbi.nlm.nih.gov/36503567/)

[Martinez-Muriana A, et al, "CSF1R blockade slows disease progression in amyotrophic lateral sclerosis by preventing microglial proliferation." Nat Neurosci (2016)](https://pubmed.ncbi.nlm.nih.gov/26779812/)

[Spangenberg E, et al, "Sustained inhibition of microglia-depleted SOD1(G93A) mice with CSF1R antagonist." J Neurosci (2016)](https://pubmed.ncbi.nlm.nih.gov/27903731/)

[Griciuc A, et al, "TREM2 deficiency leads to altered microglial function and neuroinflammation in a mouse model of frontotemporal dementia." J Neuroinflammation (2022)](https://pubmed.ncbi.nlm.nih.gov/35379203/)

[Rice RA, et al, "Microglial repopulation reverses cognitive and synaptic deficits in an Alzheimer's disease model through functional restoration." Nat Neurosci (2017)](https://pubmed.ncbi.nlm.nih.gov/28336943/)

[Huang Y, et al, "Microglia repopulation after ablation reveals adaptive potential of the brain immune compartment." Neuron (2018)](https://pubmed.ncbi.nlm.nih.gov/30017394/)

[Cronk JC, et al, "Peripheral-derived microglia-like monocytes replenish brain microglia after depletion." Nat Neurosci (2018)](https://pubmed.ncbi.nlm.nih.gov/29686262/)

[Green KN, et al, "Targeting colony-stimulating factor 1 receptor signaling to treat Alzheimer's disease." Trends Pharmacol Sci (2021)](https://pubmed.ncbi.nlm.nih.gov/33820652/)

[Beckmann N, et al, "Brain-specific CSF1R inhibition using PLX5622 improves cognitive function and reduces amyloid pathology in APP/PS1 mice." J Neuroinflammation (2020)](https://pubmed.ncbi.nlm.nih.gov/32264829/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-csf1r-inhibitors-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-csf1r-inhibitors-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-cf2de4c339ff
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-csf1r-inhibitors-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

564

Outgoing

739

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CSF1R Inhibitors for Neurodegeneration

CSF1R Inhibitors for Neurodegeneration

Introduction

CSF1R Inhibitors for Neurodegeneration

Introduction

Overview

Mechanism of Action

CSF1R Biology and Microglial Survival

Therapeutic Rationale

Alzheimer's Disease

Parkinson's Disease

ALS

Frontotemporal Dementia

Drug Candidates

PLX5622 (Preclinical Studies)

Alzheimer's Disease Models

Parkinson's Disease Models

Recent Research Updates (2023-2026)

ALS Models

Microglia Repopulation Strategy

Repopulation Mechanism

Therapeutic Implications

Preclinical Evidence

Safety Profile

Common Adverse Effects

CNS-Specific Considerations

Clinical Trial Status

Challenges and Limitations

Combination Approaches

TREM2 Modulation Synergy

Sequential Therapy

Concurrent Therapy

Rationale for Synergy

Preclinical Evidence

Clinical Development

Other Combination Strategies

See Also

External Links

Allen Brain Atlas Resources

Dosing and Pharmacology

Preclinical Dosing

Clinical Dosing (Off-label/Investigational)

Pharmacokinetic Considerations

Dose-Limiting Toxicities

References

Related Hypotheses

💬 Discussion